Thursday, July 23, 2009

New Black Box Warning for Botox

On April 30, 2009, the Food and Drug Administration (FDA) announced that it will require black box labeling on Botox and similar products warning of a rare but potentially life-threatening complication when the effects of the toxin spread far beyond the injection site. The new black box warning pertains specifically to the use of Botox to reduce spasticity or excessive muscular contractions. No serious side effects related to the distant spread of the toxin have been confirmed among people who have used Botox and the related product Myobloc for cosmetic purposes.

The new black box warnings pertain to all Botox-type products including two new
products: Myobloc and Dysport. The FDA also warns of the risks associated with
substituting one botulism product for another. The products have different
dosing units, which are incompatible, so switching products can result in
dangerous overdosing.

Related Botox, Dysport, Myobloc Links:

Dysport in Modesto, CA

Botox FAQ

Botox from Allergan



Disclaimer: This website is not intended to create a physician patient relationship. There is no specific targeted medical advice here. Please see your physician in person. This disclaimer also applies to our other websites with generalized information: Plastic Surgery Modesto CA, Plastic Surgery Modesto, Cosmetic Surgery, Acupuncture Modesto, Veins Modesto, How to Choose a Plastic Surgeon, Breast Augmentation FAQ, Tummy Tuck FAQ

No comments:

Post a Comment